# Johnson & Johnson

Source: https://onco.cc/companies/johnson-johnson/  
OnCo record `johnson-johnson` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Johnson & Johnson leads in multiple myeloma (Darzalex, Carvykti, Tecvayli, Talvey) and in bispecific antibodies for lung cancer (Rybrevant).

## Summary

Johnson & Johnson, based in New Brunswick, New Jersey, and listed as JNJ, leads in multiple myeloma with Darzalex, Carvykti, Tecvayli and Talvey and in bispecific antibodies for lung cancer with Rybrevant. Its oncology portfolio spans daratumumab, teclistamab, talquetamab, ciltacabtagene autoleucel developed with Legend, amivantamab with lazertinib, abiraterone and apalutamide in prostate cancer, TAR-200 intravesical gemcitabine for bladder cancer approved in 2025, and pasritamig, a KLK2 by CD3 bispecific. OnCo links it to the CARTITUDE-1 and CARTITUDE-4, MAIA, CEPHEUS and MajesTEC-1 papers, to the LEGEND-2 trial, to robotic bronchoscopy, and to the Yale Open Data Access project. Whether CAR-T and bispecifics move into first-line myeloma and displace daratumumab combinations is the question its own portfolio poses. Teclistamab, cilta-cel and amivantamab have their own pages.

## Fields

- Kind: Company
- Last checked: 2026-09-04
- Also known as: Alza Corporation; Janssen; Ortho Biotech Products, L.P.; Ortho Biotech; Sequus Pharmaceuticals; Centocor, Inc.; Centocor; Alza Corporation, DE, USA; Cougar Biotechnology, Inc.; Cougar Biotechnology; McNeil Consumer & Specialty Pharmaceuticals; McNeil
- HQ: New Brunswick, NJ
- Type: pharma
- Website: https://www.jnj.com
- Ticker: JNJ

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Johnson_%26_Johnson
- Official website: https://www.jnj.com

## Connected records

- fronts: [Cell Therapy](https://onco.cc/fronts/cell-therapy/), [Immunotherapy](https://onco.cc/fronts/immunotherapy/), [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- drugs: [Abiraterone acetate](https://onco.cc/drugs/abiraterone/), [Amivantamab](https://onco.cc/drugs/amivantamab/), [Apalutamide](https://onco.cc/drugs/apalutamide/), [ARX788](https://onco.cc/drugs/arx788/), [Bleximenib](https://onco.cc/drugs/bleximenib/), [Bortezomib](https://onco.cc/drugs/bortezomib/), [Cetrelimab](https://onco.cc/drugs/cetrelimab/), [Ciltacabtagene autoleucel](https://onco.cc/drugs/ciltacabtagene-autoleucel/), [Cladribine](https://onco.cc/drugs/cladribine/), [Daratumumab](https://onco.cc/drugs/daratumumab/), [Epoetin alfa](https://onco.cc/drugs/epoetin-alfa/), [Erdafitinib](https://onco.cc/drugs/erdafitinib/), [Gemcitabine intravesical system (TAR-200)](https://onco.cc/drugs/tar-200/), [Ibrutinib](https://onco.cc/drugs/ibrutinib/), [JNJ-79635322](https://onco.cc/drugs/jnj-79635322/), [JNJ-87189401](https://onco.cc/drugs/jnj-87189401/), [JNJ-90014496](https://onco.cc/drugs/jnj-90014496/), [JNJ-90301900](https://onco.cc/drugs/jnj-90301900/), [Lazertinib](https://onco.cc/drugs/lazertinib/), [Pasritamig](https://onco.cc/drugs/pasritamig/), [Siltuximab](https://onco.cc/drugs/siltuximab/), [Talquetamab](https://onco.cc/drugs/talquetamab/), [TAR-210](https://onco.cc/drugs/tar-210/), [Teclistamab](https://onco.cc/drugs/teclistamab/), [Trabectedin](https://onco.cc/drugs/trabectedin/)
- companies: [Firefly Bio](https://onco.cc/companies/firefly-bio/), [Halda Therapeutics](https://onco.cc/companies/halda-therapeutics/), [Johnson & Johnson Innovation - JJDC](https://onco.cc/companies/jjdc/), [Otsuka Pharmaceutical](https://onco.cc/companies/otsuka/)
- trials: [A Long-term Extension Study of PCI-32765 (Ibrutinib)](https://onco.cc/trials/nct01804686/), [A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma](https://onco.cc/trials/nct07258511/), [A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma](https://onco.cc/trials/nct07518186/), [A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination Wi](https://onco.cc/trials/nct05455320/), [A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortez](https://onco.cc/trials/nct06208150/), [A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With](https://onco.cc/trials/nct05572515/), [A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relaps](https://onco.cc/trials/nct07589634/), [A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer](https://onco.cc/trials/nct04557059/), [A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer](https://onco.cc/trials/nct06385080/), [A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer](https://onco.cc/trials/nct05488314/), [A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy](https://onco.cc/trials/nct06750094/), [A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure](https://onco.cc/trials/nct04988295/), [A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer](https://onco.cc/trials/nct06662786/), [A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer](https://onco.cc/trials/nct07227025/), [A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer](https://onco.cc/trials/nct07276399/), [A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)](https://onco.cc/trials/nct06667076/), [A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer](https://onco.cc/trials/nct05498428/), [A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer](https://onco.cc/trials/nct05379595/), [A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC](https://onco.cc/trials/nct05884398/), [A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer](https://onco.cc/trials/nct01946204/), [A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC](https://onco.cc/trials/nct02489318/), [A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma](https://onco.cc/trials/nct04325828/), [A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy](https://onco.cc/trials/nct03767244/), [A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)](https://onco.cc/trials/nct06852222/), [A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma](https://onco.cc/trials/nct06550895/), [A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions](https://onco.cc/trials/nct04538664/), [A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer](https://onco.cc/trials/nct05908734/), [A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy](https://onco.cc/trials/nct04023526/), [A Study of Daratumumab](https://onco.cc/trials/nct05438043/), [A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Ind](https://onco.cc/trials/nct06577025/), [A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer](https://onco.cc/trials/nct03473743/), [A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Mul](https://onco.cc/trials/nct04133636/), [A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma](https://onco.cc/trials/nct07266441/), [A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma](https://onco.cc/trials/nct05421663/), [A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)](https://onco.cc/trials/nct06667908/), [A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)](https://onco.cc/trials/nct05388669/), [A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC](https://onco.cc/trials/nct07586202/), [A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer](https://onco.cc/trials/nct03431350/), [A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)](https://onco.cc/trials/nct04497844/), [A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer](https://onco.cc/trials/nct07225946/), [A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)](https://onco.cc/trials/mcrpc/), [A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)](https://onco.cc/trials/hr-nmibc/), [A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder](https://onco.cc/trials/nct04658862/), [A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)](https://onco.cc/trials/nct06211764/), [A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal](https://onco.cc/trials/nct05552222/), [A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma](https://onco.cc/trials/nct04586426/), [A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate](https://onco.cc/trials/nct01517802/), [A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia](https://onco.cc/trials/nct05963074/), [A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel](https://onco.cc/trials/nct07149857/), [A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events](https://onco.cc/trials/nct06500884/), [A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer](https://onco.cc/trials/nct06919965/), [A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer](https://onco.cc/trials/nct06319820/), [A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers](https://onco.cc/trials/nct02908906/), [An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)](https://onco.cc/trials/nct02257736/), [An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer](https://onco.cc/trials/nct02365597/), [An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS](https://onco.cc/trials/nct02531516/), [AQUILA](https://onco.cc/trials/aquila/), [CARTITUDE-1](https://onco.cc/trials/cartitude-1/), [CARTITUDE-4](https://onco.cc/trials/cartitude-4/), [CARTITUDE-5](https://onco.cc/trials/cartitude-5/), [CARTITUDE-6](https://onco.cc/trials/cartitude-6/), [CASSIOPEIA](https://onco.cc/trials/cassiopeia/), [CEPHEUS](https://onco.cc/trials/cepheus/), [CHRYSALIS](https://onco.cc/trials/chrysalis/), [CLL12](https://onco.cc/trials/cll12/), [COU-AA-301](https://onco.cc/trials/cou-aa-301/), [COU-AA-302](https://onco.cc/trials/cou-aa-302/), [DRAMMATIC](https://onco.cc/trials/drammatic/), [Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib](https://onco.cc/trials/nct06120140/), [GLOW](https://onco.cc/trials/glow/), [JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC](https://onco.cc/trials/nct04892173/), [LATITUDE](https://onco.cc/trials/latitude/), [LEGEND-2](https://onco.cc/trials/legend-2/), [MAGNITUDE](https://onco.cc/trials/magnitude/), [MAIA](https://onco.cc/trials/maia/), [MajesTEC-1](https://onco.cc/trials/majestec-1/), [MajesTEC-3](https://onco.cc/trials/majestec-3/), [MARIPOSA](https://onco.cc/trials/mariposa/), [MonumenTAL-1](https://onco.cc/trials/monumental-1/), [PERSEUS](https://onco.cc/trials/perseus/), [Premedication to Reduce Amivantamab Associated Infusion Related Reactions](https://onco.cc/trials/nct05663866/), [RESONATE](https://onco.cc/trials/resonate/), [RESONATE-2](https://onco.cc/trials/resonate-2/), [SHINE](https://onco.cc/trials/shine/), [Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer](https://onco.cc/trials/nct05316155/), [Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer](https://onco.cc/trials/nct06800313/), [SunRISe-1](https://onco.cc/trials/sunrise-1/), [SYMPATICO](https://onco.cc/trials/sympatico/), [THOR](https://onco.cc/trials/thor/)
- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/), [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/), [EGFR-mutated non-small-cell lung cancer](https://onco.cc/cancers/egfr-mutant-nsclc/), [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/), [Kaposi sarcoma](https://onco.cc/cancers/kaposi-sarcoma/), [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Primary CNS lymphoma](https://onco.cc/cancers/primary-cns-lymphoma/), [Prostate cancer](https://onco.cc/cancers/prostate/), [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/), [Waldenström macroglobulinaemia](https://onco.cc/cancers/waldenstrom/)
- technologies: [Microwave and radiofrequency ablation systems](https://onco.cc/technologies/microwave-rf-ablation/), [Robotic and navigational bronchoscopy](https://onco.cc/technologies/robotic-bronchoscopy/), [Surgical robots: da Vinci, Hugo, Versius and single-port systems](https://onco.cc/technologies/surgical-robot-platforms/), [Thermal ablation (RFA, microwave, cryo)](https://onco.cc/technologies/thermal-ablation/)
- ideas: [Test every man for DNA repair faults on the day his prostate cancer is found to have spread, not three treatments later](https://onco.cc/ideas/idea-prostate-hrr-testing-at-metastatic-diagnosis/)
- key papers: [CARTITUDE-1: cilta-cel, a BCMA CAR-T, in heavily pretreated myeloma](https://onco.cc/key-papers/paper-cartitude-1-cilta-cel-lancet-2021/), [CARTITUDE-4: cilta-cel CAR-T versus standard combinations after one to three prior lines of myeloma therapy](https://onco.cc/key-papers/paper-cartitude-4-cilta-cel-nejm-2023/), [CEPHEUS: daratumumab quadruplet for newly diagnosed myeloma patients not having a transplant, with MRD-negativity as the main endpoint](https://onco.cc/key-papers/paper-cepheus-dara-vrd-natmed-2025/), [Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma](https://onco.cc/key-papers/paper-shine-ibrutinib-bendamustine-rituximab-mantle-cell-nejm-2022/), [MAIA: adding daratumumab to lenalidomide-dexamethasone for older patients with newly diagnosed myeloma who cannot have a transplant](https://onco.cc/key-papers/paper-maia-daratumumab-rd-nejm-2019/), [MajesTEC-1: teclistamab, an off-the-shelf BCMA bispecific antibody, in heavily pretreated myeloma](https://onco.cc/key-papers/paper-majestec-1-teclistamab-nejm-2022/), [MARIPOSA: amivantamab plus lazertinib versus osimertinib as first treatment for EGFR-mutated lung cancer](https://onco.cc/key-papers/paper-mariposa-nejm-2024/), [PERSEUS: daratumumab added to bortezomib-lenalidomide-dexamethasone around autologous transplant in newly diagnosed myeloma](https://onco.cc/key-papers/paper-perseus-dara-vrd-transplant-nejm-2024/), [STAMPEDE: adding abiraterone to hormone therapy at diagnosis of advanced prostate cancer](https://onco.cc/key-papers/paper-stampede-abiraterone-nejm-2017/), [SunRISe-1: TAR-200, a gemcitabine-releasing device placed in the bladder, for BCG-unresponsive non-muscle-invasive bladder cancer](https://onco.cc/key-papers/paper-sunrise-1-jco-2025/)
- roadmaps: [Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting](https://onco.cc/roadmaps/lymphoma-roadmap/)
- people: [Ryan Schoenfeld](https://onco.cc/people/ryan-schoenfeld/)
- institutions: [Comprehensive Cancer Center Mainfranken, University Hospital Würzburg](https://onco.cc/institutions/ccc-wuerzburg/), [Yale University Open Data Access (YODA) Project](https://onco.cc/institutions/yoda-project/)

---
JSON: https://onco.cc/api/v1/entities/johnson-johnson.json